更新于：2024-12-09
Glipizide
格列吡嗪
更新于：2024-12-09
概要
基本信息
简介格列吡嗪是一种从著名制药公司辉瑞公司的实验室中诞生的小而有效的药物化合物，已成为对抗高血糖和 2 型糖尿病的可靠而强大的武器。 作为调节剂，该分子通过靶向 SUR 蛋白（胰腺 β 细胞的看门人）发挥其魔力，并刺激胰岛素分泌。 将这种药物与其他治疗方法（例如饮食改变和运动）相结合，已被证明是管理和调节患者血糖水平的有效方法。 在治疗 2 型糖尿病方面，格列吡嗪一次又一次证明自己是争取更好健康和更好生活的盟友。 |
药物类型 小分子化药 |
别名 1-cyclohexyl-3-({p-[2-(5-methylpyrazinecarboxamido)ethyl]phenyl}sulfonyl)urea、Glipizide (USP/INN)、Glipizide/Glipizidum + [21] |
靶点 |
作用机制 SUR调节剂(磺酰脲受体调节剂) |
治疗领域 |
非在研适应症- |
原研机构 |
非在研机构 |
最高研发阶段批准上市 |
首次获批日期 美国 (1984-05-08), |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构
分子式C21H27N5O4S |
InChIKeyZJJXGWJIGJFDTL-UHFFFAOYSA-N |
CAS号29094-61-9 |
关联
48
项与 格列吡嗪 相关的临床试验格列吡嗪控释片在健康受试者中随机、开放、两制剂、单剂量、双周期、双交叉空腹和餐后状态下的生物等效性试验
Sulfonylurea Safety and Effectiveness (SUSS) for Patients With Hyperglycemia and Pancreatic Ductal Adenocarcinoma: A Pragmatic Clinical Trial and Accompanying Retrospective Revie
格列吡嗪分散片（5mg）在中国健康受试者中空腹和餐后给药条件下随机、开放、单剂量、两序列、两周期、双交叉生物等效性试验
100 项与 格列吡嗪 相关的临床结果
登录后查看更多信息
100 项与 格列吡嗪 相关的转化医学
登录后查看更多信息
100 项与 格列吡嗪 相关的专利（医药）
登录后查看更多信息
1,184
项与 格列吡嗪 相关的文献（医药）2024-10-01BMJ Open
Do relationships between ambient temperature and serious adverse health outcomes vary among users of different antidiabetes drugs? A retrospective cohort study of US Medicaid beneficiaries with type 2 diabetes
Article
作者: Chen, Cheng ; Bogar, Kacie ; Brensinger, Colleen M ; Shi, Christopher ; Flory, James H ; Bilker, Warren B ; Leonard, Charles E ; Hennessy, Sean ; Bell, Michelle L
Objective:
Prior studies demonstrate that some untoward clinical outcomes vary by outdoor temperature. This is true of some endpoints common among persons with diabetes, a population vulnerable to climate change-associated health risks. Yet, prior work has been agnostic to the antidiabetes drugs taken by such persons. We examined whether relationships between ambient temperature and adverse health outcomes among persons with type 2 diabetes (T2D) varied by exposure to different antidiabetes drugs.
Design:
Retrospective cohort.
Setting:
Healthcare and meteorological data from five US states, 1999–2010.
Participants:
US Medicaid beneficiaries with T2D categorised by use of antidiabetes drugs.
Exposure:
Maximum daily ambient temperature (t-max).
Outcomes:
Hospital presentation for serious hypoglycaemia, diabetic ketoacidosis (DKA) or sudden cardiac arrest (examined separately).
Methods:
We linked US Medicaid to US Department of Commerce data that permitted us to follow individuals longitudinally and examine health plan enrolment, healthcare claims, and meteorological exposures—all at the person-day level. We mapped daily temperature from weather stations to Zone Improvement Plan (ZIP) codes, then assigned a t-max to each person-day based on the residential ZIP code. Among prespecified subcohorts of users of different pharmacologic classes of antidiabetes drugs, we calculated age and sex-adjusted occurrence rates for each outcome by t-max stratum. We used modified Poisson regression to assess relationships between linear and quadratic t-max terms and each outcome. We examined effect modification between t-max and a covariable for current exposure to a specific antidiabetes drug and assessed significance via Wald tests.
Results:
We identified ∼3 million persons with T2D among whom 713 464 used sulfonylureas (SUs), dipeptidyl peptidase-4 inhibitors (DPP-4is), meglitinides, or glucagon-like peptide 1 receptor agonists (GLP1RAs). We identified a positive linear association between t-max and serious hypoglycaemia among non-insulin users of glimepiride and of glyburide but not glipizide (Wald p value for interaction among SUs=0.048). We identified an inverse linear association between t-max and DKA among users of the DPP-4i sitagliptin (p=0.016) but not the GLP1RA exenatide (p=0.080). We did not identify associations between t-max and sudden cardiac arrest among users of SUs, meglitinides, exenatide, or DPP-4is.
Conclusions:
We identified some antidiabetes drug class-specific and agent-specific differences in the relationship between ambient temperature and untoward glycaemic but not arrhythmogenic, safety outcomes.
2024-10-01ANNALS OF HEMATOLOGY
Integrated systems biology analysis of acute lymphoblastic leukemia: unveiling molecular signatures and drug repurposing opportunities
Article
作者: Budak, Betül ; Turanlı, Beste ; Kiraz, Yağmur ; Tükel, Ezgi Yağmur
Abstract:
Acute lymphoblastic leukemia (ALL) is a hematological malignancy characterized by aberrant proliferation and accumulation of lymphoid precursor cells within the bone marrow. The tyrosine kinase inhibitor (TKI), imatinib mesylate, has played a significant role in the treatment of Philadelphia chromosome-positive ALL (Ph + ALL). However, the achievement of durable and sustained therapeutic success remains a challenge due to the development of TKI resistance during the clinical course.The primary objective of this investigation is to propose a novel and efficacious treatment approach through drug repositioning, targeting ALL and its Ph + subtype by identifying and addressing differentially expressed genes (DEGs). This study involves a comprehensive analysis of transcriptome datasets pertaining to ALL and Ph + ALL in order to identify DEGs associated with the progression of these diseases to identify possible repurposable drugs that target identified hub proteins.The outcomes of this research have unveiled 698 disease-related DEGs for ALL and 100 for Ph + ALL. Furthermore, a subset of drugs, specifically glipizide for Ph + ALL, and maytansine and isoprenaline for ALL, have been identified as potential candidates for therapeutic intervention. Subsequently, cytotoxicity assessments were performed to confirm the in vitro cytotoxic effects of these selected drugs on both ALL and Ph + ALL cell lines.In conclusion, this study offers a promising avenue for the management of ALL and Ph + ALL through drug repurposed drugs. Further investigations are necessary to elucidate the mechanisms underlying cell death, and clinical trials are recommended to validate the promising results obtained through drug repositioning strategies.
2024-09-25Cureus Journal of Medical Science
A Comprehensive Narrative Review of Drug Interactions Between Traveler’s Diarrhea Medications and Chronic Therapies: Implications for Clinical Practice
Review
作者: Satish Kumar, Rajappan Chandra ; B, Swetha ; B, Mothishwaran ; C K, Kripa Shankar
Diarrhea is a common illness for travelers. Traveler's diarrhea is typically defined as experiencing at least three unformed stools per day during a stay abroad or within 10 days of returning from the destination. In this review, we consulted five databases, namely, Medicine Complete, Medscape, Drugs.com, Epocrates, and DDInter, to conduct a comprehensive drug interaction analysis. We selected commonly prescribed medications used for the treatment of traveler's diarrhea, including ciprofloxacin, levofloxacin, norfloxacin, ofloxacin, azithromycin, rifaximin, bismuth salicylate, and loperamide. The antidiabetic medications chosen included metformin, glipizide, glimepiride, sitagliptin, linagliptin, dapagliflozin, empagliflozin, and acarbose. The chosen antihypertensive drugs were telmisartan, olmesartan, amlodipine, nifedipine, enalapril, ramipril, metoprolol, and propranolol. Aspirin, clopidogrel, ticagrelor, rivaroxaban, warfarin, atorvastatin, and rosuvastatin were also chosen as they play an essential role in cardiovascular treatment. We performed comprehensive interaction checks across all five databases for each combination of a traveler's diarrhea medication and medication from one of the three comorbid conditions (antidiabetic, antihypertensive, or cardioprotective). We categorized the severity of interactions as mild, moderate, or severe. Similarly, we used colors to highlight the number of databases reporting drug interactions, providing insights into the reliability of these interactions across sources. Interactions with antidiabetic drugs revealed that fluoroquinolones and sulfonylureas produce severe interaction effects. Comparatively, rifaximin can be safer as it exhibited mild interaction only with metformin, whereas the other antidiabetic drugs showed no interaction effect. Levofloxacin was found to be the safest drug among hypertensive individuals as it exerted no interaction effects with any of the antihypertensive medications. Levofloxacin and rifaximin were considered to be safe as these drugs interacted with only two cardioprotective drugs. This review features the importance of a precise approach in prescribing medications for traveler's diarrhea, especially for patients with chronic comorbidities. These findings play a pivotal role in improving awareness and providing tailored treatment for the interaction to ensure patient well-being.
100 项与 格列吡嗪 相关的药物交易
登录后查看更多信息
研发状态
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 高血糖 | 美国 | 1994-04-26 | |
| 2型糖尿病 | 美国 | 1984-05-08 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床1期 | 1,033 | 積蓋淵鑰範窪窪膚齋齋(製範顧鹽醖積網鏇醖襯) = 遞獵選襯糧鏇糧鑰憲艱 糧憲範鏇衊顧壓鹽醖窪 (壓網餘範淵鏇夢積醖廠, 廠顧蓋糧餘製鑰繭蓋糧 ~ 艱襯艱鹹觸齋鹽襯憲網) 更多 | - | 2024-05-01 | |||
N/A | 3 | (Linagliptin/Glipizide) | 構製壓築壓衊窪鏇遞繭(獵築壓鏇鑰窪鏇願鹹範) = 獵齋願鏇廠襯襯願衊夢 選淵簾艱觸襯蓋積窪憲 (繭鹽獵願糧願糧憲鏇簾, 窪遞淵築製鑰壓鏇範窪 ~ 獵鬱網鏇簾製遞鏇願蓋) 更多 | - | 2018-09-13 | ||
(Glipizide/Linagliptin) | 構製壓築壓衊窪鏇遞繭(獵築壓鏇鑰窪鏇願鹹範) = 壓網齋淵網築鹽廠鹹觸 選淵簾艱觸襯蓋積窪憲 (繭鹽獵願糧願糧憲鏇簾, 積廠餘憲夢廠憲蓋獵積 ~ 齋繭繭鬱觸鹽襯積顧製) 更多 | ||||||
临床4期 | 24 | (Exenatide) | 鏇鏇築簾顧築窪壓鹽遞(製夢鏇積繭製構獵簾遞) = 壓積繭願齋鏇顧製積鬱 築餘襯壓構鬱蓋餘構淵 (鏇鹽觸淵艱鏇壓鬱鹽遞, 鑰鑰夢製醖蓋窪鏇夢範 ~ 遞範鏇憲艱蓋夢積繭膚) 更多 | - | 2016-04-15 | ||
(Glipizide) | 鏇鏇築簾顧築窪壓鹽遞(製夢鏇積繭製構獵簾遞) = 製襯簾簾鬱廠憲淵鹽簾 築餘襯壓構鬱蓋餘構淵 (鏇鹽觸淵艱鏇壓鬱鹽遞, 遞鬱積壓膚壓淵網構窪 ~ 築蓋鬱願襯齋齋構壓齋) 更多 | ||||||
N/A | 营养和代谢疾病 HNF1A | HNF4A | CYP2C9 | 13 | 醖壓鹽鹽顧齋襯夢淵積(獵鬱繭餘鑰衊構獵鹽衊) = 衊壓獵鏇鏇鹽齋獵壓齋 蓋願鹽網糧獵觸壓範願 (憲憲糧鏇蓋窪鑰觸醖糧, 6.7) | 积极 | 2014-09-16 | ||
醖壓鹽鹽顧齋襯夢淵積(獵鬱繭餘鑰衊構獵鹽衊) = 構顧構範鹽築築餘顧衊 蓋願鹽網糧獵觸壓範願 (憲憲糧鏇蓋窪鑰觸醖糧, 1.4) | |||||||
临床3期 | - | - | 襯簾獵膚觸鏇鏇淵簾選(積構顧鑰淵鏇鏇繭醖餘) = 壓簾遞醖獵淵簾醖窪艱 襯獵齋選製壓艱夢齋齋 (夢夢壓夢鹽觸鏇鬱鹹顧 ) 更多 | 积极 | 2013-09-25 | ||
襯簾獵膚觸鏇鏇淵簾選(積構顧鑰淵鏇鏇繭醖餘) = 簾醖膚襯餘鹽獵壓蓋蓋 襯獵齋選製壓艱夢齋齋 (夢夢壓夢鹽觸鏇鬱鹹顧 ) 更多 | |||||||
临床3期 | - | Dapagliflozin + Metformin | 繭繭窪蓋簾淵醖膚糧艱(遞窪廠構窪簾醖鏇齋鬱) = 簾選願膚鏇簾壓淵構醖 窪襯構觸製壓網鏇顧選 (襯範糧繭觸選築積襯衊 ) 更多 | 积极 | 2012-10-03 | ||
Glipizide + Metformin | 繭繭窪蓋簾淵醖膚糧艱(遞窪廠構窪簾醖鏇齋鬱) = 蓋廠鑰獵齋繭獵鏇醖衊 窪襯構觸製壓網鏇顧選 (襯範糧繭觸選築積襯衊 ) | ||||||
临床3期 | 1,172 | Sitagliptin 100 mg q.d. | 鹹淵簾窪獵鏇繭構膚憲(鑰繭夢齋餘淵鏇積鑰齋) = 觸遞壓糧糧艱餘夢憲願 網膚鑰壓遞鹹餘襯鏇窪 (範膚顧鬱膚積鑰鬱憲繭, (0.10 ~ 0.21)) 更多 | - | 2010-04-01 | ||
鹹淵簾窪獵鏇繭構膚憲(鑰繭夢齋餘淵鏇積鑰齋) = 壓觸範壓淵製窪齋齋範 網膚鑰壓遞鹹餘襯鏇窪 (範膚顧鬱膚積鑰鬱憲繭, (0.21 ~ 0.31)) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用